Industry · 30 scored · 211 listed

Biotechnology Stocks in the US

The 30 Biotechnology companies we score in the US are Vertex Pharmaceuticals Incorporated ($139.3B, the largest), Moderna, Inc., Regeneron Pharmaceuticals, Inc. and 27 more. 21 of the 30 companies we score beat S&P 500 on share price over recent months (3 have no relative-strength reading yet). Prices are as of 4 Nov 2026.

Biotechnology: Regeneron Pharmaceuticals, Inc. owns the largest revenue base; Ascendis Pharma A/S has the fastest current growth.

30Companies scored on this page, of 211 listed

$875.9BCombined market value all of them together

20/24Revenue growing revenue over the last 12 months up on a year earlier

21/30Beating S&P 500 share price doing better than the index (relative strength) (3 have no reading yet)

21 of 30 beat the S&P 500 on share price over recent months

The main question: the biggest companies are not always the ones changing the most.

Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.

By Sector AlphaUpdated November 2026Prices as of 4 November 2026How the numbers are worked out

Which are the biggest Biotechnology stocks in the US?

The largest Biotechnology stocks in the US by market value are Vertex Pharmaceuticals Incorporated ($139.3B), Moderna, Inc. ($103.2B) and Regeneron Pharmaceuticals, Inc. ($93.4B), at prices of 4 Nov 2026.

Vertex Pharmaceuticals Incorporated: $549.30 | market value $139.3B | P/E 28.6
Moderna, Inc.: $258.48 | market value $103.2B
Regeneron Pharmaceuticals, Inc.: $930.68 | market value $93.4B | P/E 14.7
argenx SE: $931.80 | market value $59.1B | P/E 32
BeOne Medicines AG: $376.66 | market value $42.8B | P/E 48.3
Revolution Medicines, Inc.: $199.34 | market value $42.7B
Royalty Pharma plc: $67.53 | market value $38.8B | P/E 30.5
Genmab A/S: $55.10 | market value $31.9B | P/E 21.4
Roivant Sciences: $38.23 | market value $27.6B
Incyte Corporation: $122.85 | market value $25.0B | P/E 14

The other 20 Biotechnology companies are in the full list below.

Share price | market value | P/E, biggest first. Prices and market values as of 4 Nov 2026; ratios as in the score list below.

Which are the Biotechnology stocks, ranked?

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 4 Nov 2026.

1Exelixis, Inc.EXEL · $17.8B76.0of 100favourable · strongest on ROCE and PEG
2Halozyme Therapeutics, Inc.HALO · $14.8B71.1of 100favourable · strongest on ROCE and PEG
3Caris Life Sciences, Inc.CAI · $9.4B65.7of 100favourable · strongest on ROCE improvement and relative strength versus sector
4Incyte CorporationINCY · $25.0B64.3of 100mixed, leaning good · strongest on ROCE and profit growth
5Genmab A/SGMAB · $31.9B60.8of 100mixed, leaning good · strongest on PEG and relative strength versus sector
6argenx SEARGX · $59.1B58.8of 100mixed, leaning good · strongest on ROCE and ROCE improvement
7Kymera Therapeutics, Inc.KYMR · $11.6B57.6of 100mixed, leaning good · strongest on relative strength versus sector and margin improvement
8Vertex Pharmaceuticals IncorporatedVRTX · $139.3B56.1of 100mixed, leaning good · strongest on ROCE and profitable quarters
9Spyre Therapeutics, Inc.SYRE · $9.3B55.8of 100provisional · strongest on relative strength versus sector and margin improvement
10BeOne Medicines AGONC · $42.8B54.9of 100mixed, leaning good · strongest on ROCE improvement and 13-week relative-strength change

Which Biotechnology companies are listed in the US?

The largest 15 of 30 listed US Biotechnology companies are named here; all 30 are ranked in the scorecard. Every figure is equal-weighted across those companies and carries its own as-of date. One large company cannot set the reading.

Vertex Pharmaceuticals Incorporated$139.3B
Moderna, Inc.$103.2B
Regeneron Pharmaceuticals, Inc.$93.4B
argenx SE$59.1B
BeOne Medicines AG$42.8B
Revolution Medicines, Inc.$42.7B
Royalty Pharma plc$38.8B
Genmab A/S$31.9B
Roivant Sciences Ltd.$27.6B
Incyte Corporation$25.0B
Insmed Incorporated$24.1B
BioNTech SE$22.5B
Alnylam Pharmaceuticals, Inc.$21.6B
Exelixis, Inc.$17.8B
Ascendis Pharma A/S$16.9B

The remaining 15 Biotechnology companies are named and ranked in the scorecard.

How many Biotechnology companies are listed in the US?

211 Biotechnology companies in the Biotechnology industry group (every listed company) have a page on Sector Alpha, by market value as of 4 November 2026, and all 211 are listed below, largest first. The largest is Vertex Pharmaceuticals Incorporated ($139.3 billion) and the smallest with a market value is EyePoint, Inc.

Every Biotechnology company with a page, largest first
Company	Market value
1. Vertex Pharmaceuticals Incorporated VRTX	$139.3 billion
2. Moderna, Inc. MRNA	$103.2 billion
3. Regeneron Pharmaceuticals, Inc. REGN	$93.4 billion
4. argenx SE ARGX	$59.1 billion
5. BeOne Medicines AG ONC	$42.8 billion
6. Revolution Medicines, Inc. RVMD	$42.7 billion
7. Royalty Pharma plc RPRX	$38.8 billion
8. Genmab A/S GMAB	$31.9 billion
9. Roivant Sciences Ltd. ROIV	$27.6 billion
10. Incyte Corporation INCY	$25 billion
11. Insmed Incorporated INSM	$24.1 billion
12. BioNTech SE BNTX	$22.5 billion
13. Alnylam Pharmaceuticals, Inc. ALNY	$21.6 billion
14. Exelixis, Inc. EXEL	$17.8 billion
15. Ascendis Pharma A/S ASND	$16.9 billion
16. BridgeBio Pharma, Inc. BBIO	$15.2 billion
17. Jazz Pharmaceuticals plc JAZZ	$15.1 billion
18. Halozyme Therapeutics, Inc. HALO	$14.8 billion
19. Summit Therapeutics Inc. SMMT	$12.9 billion
20. Kymera Therapeutics, Inc. KYMR	$11.6 billion
21. Bio-Techne Corporation TECH	$11.4 billion
22. BioMarin Pharmaceutical Inc. BMRN	$11.1 billion
23. ImmunityBio, Inc. IBRX	$9.5 billion
24. Caris Life Sciences, Inc. CAI	$9.4 billion
25. Madrigal Pharmaceuticals, Inc. MDGL	$9.3 billion
26. Protagonist Therapeutics, Inc. PTGX	$9.3 billion
27. Spyre Therapeutics, Inc. SYRE	$9.3 billion
28. Krystal Biotech, Inc. KRYS	$9.2 billion
29. Crinetics Pharmaceuticals, Inc. CRNX	$9 billion
30. Cytokinetics, Incorporated CYTK	$8.8 billion
31. TG Therapeutics, Inc. TGTX	$8.7 billion
32. Arrowhead Pharmaceuticals, Inc. ARWR	$8.7 billion
33. Corcept Therapeutics Incorporated CORT	$8.7 billion
34. Praxis Precision Medicines, Inc. PRAX	$8 billion
35. ABIVAX Société Anonyme ABVX	$7.8 billion
36. Rhythm Pharmaceuticals, Inc. RYTM	$7.7 billion
37. Axsome Therapeutics, Inc. AXSM	$7.2 billion
38. Ionis Pharmaceuticals, Inc. IONS	$6.7 billion
39. Mirum Pharmaceuticals, Inc. MIRM	$6.3 billion
40. Ligand Pharmaceuticals Incorporated LGND	$6.3 billion
41. CG Oncology, Inc. CGON	$6 billion
42. PTC Therapeutics, Inc. PTCT	$5.8 billion
43. Scholar Rock Holding Corporation SRRK	$5.6 billion
44. Travere Therapeutics, Inc. TVTX	$5 billion
45. CRISPR Therapeutics AG CRSP	$5 billion
46. Dianthus Therapeutics, Inc. DNTH	$4.8 billion
47. Legend Biotech Corporation LEGN	$4.4 billion
48. Arcutis Biotherapeutics, Inc. ARQT	$4.3 billion
49. AbCellera Biologics Inc. ABCL	$4 billion
50. Relay Therapeutics, Inc. RLAY	$4 billion
51. Iovance Biotherapeutics, Inc. IOVA	$3.9 billion
52. Tango Therapeutics, Inc. TNGX	$3.9 billion
53. Catalyst Pharmaceuticals, Inc. CPRX	$3.9 billion
54. Xenon Pharmaceuticals Inc. XENE	$3.8 billion
55. ACADIA Pharmaceuticals Inc. ACAD	$3.7 billion
56. Tarsus Pharmaceuticals, Inc. TARS	$3.4 billion
57. Denali Therapeutics Inc. DNLI	$3.4 billion
58. Viridian Therapeutics, Inc. VRDN	$3.3 billion
59. Telix Pharmaceuticals Limited TLX	$3.2 billion
60. IDEAYA Biosciences, Inc. IDYA	$3.1 billion
61. Zai Lab Limited ZLAB	$2.8 billion
62. Arcus Biosciences, Inc. RCUS	$2.8 billion
63. Beam Therapeutics Inc. BEAM	$2.8 billion
64. AtaiBeckley Inc. ATAI	$2.7 billion
65. Xencor, Inc. XNCR	$2.6 billion
66. NewAmsterdam Pharma Company N.V. NAMS	$2.5 billion
67. Recursion Pharmaceuticals, Inc. RXRX	$2.4 billion
68. Celldex Therapeutics, Inc. CLDX	$2.4 billion
69. ADMA Biologics, Inc. ADMA	$2.3 billion
70. Vericel Corporation VCEL	$2.3 billion
71. Immunome, Inc. IMNM	$2.3 billion
72. Aurinia Pharmaceuticals Inc. AUPH	$2.3 billion
73. Septerna, Inc. SEPN	$2.2 billion
74. Zymeworks Inc. ZYME	$2.2 billion
75. Lakefront Biotherapeutics NV LKFT	$2.1 billion
76. Fortrea Holdings Inc. FTRE	$2 billion
77. Sarepta Therapeutics, Inc. SRPT	$2 billion
78. Maravai LifeSciences Holdings, Inc. MRVI	$2 billion
79. Harmony Biosciences Holdings, Inc. HRMY	$2 billion
80. Vir Biotechnology, Inc. VIR	$2 billion
81. Mesoblast Limited MESO	$1.9 billion
82. Agios Pharmaceuticals, Inc. AGIO	$1.9 billion
83. Zenas BioPharma, Inc. ZBIO	$1.9 billion
84. Generate Biomedicines, Inc. GENB	$1.8 billion
85. Precigen, Inc. PGEN	$1.8 billion
86. Absci Corporation ABSI	$1.8 billion
87. Stoke Therapeutics, Inc. STOK	$1.8 billion
88. Novavax, Inc. NVAX	$1.8 billion
89. Nurix Therapeutics, Inc. NRIX	$1.7 billion
90. Intellia Therapeutics, Inc. NTLA	$1.7 billion
91. Ultragenyx Pharmaceutical Inc. RARE	$1.7 billion
92. Nuvation Bio Inc. NUVB	$1.7 billion
93. uniQure N.V. QURE	$1.6 billion
94. Ocular Therapeutix, Inc. OCUL	$1.6 billion
95. Innoviva, Inc. INVA	$1.5 billion
96. Nanobiotix S.A. NBTX	$1.5 billion
97. Immunocore Holdings plc IMCR	$1.5 billion
98. Taysha Gene Therapies, Inc. TSHA	$1.4 billion
99. AnaptysBio, Inc. ANAB	$1.4 billion
100. UroGen Pharma Ltd. URGN	$1.4 billion
101. Ascentage Pharma Group International AAPG	$1.3 billion
102. Nektar Therapeutics NKTR	$1.3 billion
103. Inhibrx Biosciences, Inc. INBX	$1.3 billion
104. MannKind Corporation MNKD	$1.3 billion
105. Verastem, Inc. VSTM	$1.2 billion
106. Silence Therapeutics plc SLN	$1.2 billion
107. Janux Therapeutics, Inc. JANX	$1.1 billion
108. Rigel Pharmaceuticals, Inc. RIGL	$958 million
109. Immatics N.V. IMTX	$945 million
110. Syndax Pharmaceuticals, Inc. SNDX	$941 million
111. Inventiva S.A. IVA	$940 million
112. Odyssey Therapeutics, Inc. ODTX	$934 million
113. Monte Rosa Therapeutics, Inc. GLUE	$923 million
114. MeiraGTx Holdings plc MGTX	$905 million
115. Prime Medicine, Inc. PRME	$884 million
116. Theravance Biopharma, Inc. TBPH	$884 million
117. Pharming Group N.V. PHAR	$880 million
118. Aktis Oncology, Inc. AKTS	$845 million
119. Ardelyx, Inc. ARDX	$827 million
120. Arbutus Biopharma Corporation ABUS	$803 million
121. Ginkgo Bioworks Holdings, Inc. DNA	$785 million
122. OmniAb, Inc. OABI	$756 million
123. Wave Life Sciences Ltd. WVE	$714 million
124. XOMA Royalty Corporation XOMA	$710 million
125. Solid Biosciences Inc. SLDB	$699 million
126. Geron Corporation GERN	$694 million
127. Candel Therapeutics, Inc. CADL	$692 million
128. 4D Molecular Therapeutics, Inc. FDMT	$678 million
129. Kura Oncology, Inc. KURA	$677 million
130. Zevra Therapeutics, Inc. ZVRA	$665 million
131. Lexicon Pharmaceuticals, Inc. LXRX	$659 million
132. SL Science Holding Limited SLBT	$633 million
133. DBV Technologies S.A. DBVT	$622 million
134. Crescent Biopharma, Inc. CBIO	$592 million
135. Aclaris Therapeutics, Inc. ACRS	$570 million
136. Surrozen, Inc. SRZN	$554 million
137. Puma Biotechnology, Inc. PBYI	$552 million
138. Valneva SE VALN	$539 million
139. Ovid Therapeutics Inc. OVID	$535 million
140. Capricor Therapeutics, Inc. CAPR	$519 million
141. Shattuck Labs, Inc. STTK	$517 million
142. CytomX Therapeutics, Inc. CTMX	$512 million
143. REGENXBIO Inc. RGNX	$509 million
144. YD Bio Limited YDES	$492 million
145. Arvinas, Inc. ARVN	$486 million
146. Gyre Therapeutics, Inc. GYRE	$471 million
147. MiMedx Group, Inc. MDXG	$467 million
148. Phathom Pharmaceuticals, Inc. PHAT	$451 million
149. Oculis Holding AG OCS	$449 million
150. CorMedix Inc. CRMD	$441 million
151. Prothena Corporation plc PRTA	$431 million
152. Prelude Therapeutics Incorporated PRLD	$420 million
153. Editas Medicine, Inc. EDIT	$418 million
154. Altimmune, Inc. ALT	$412 million
155. Allogene Therapeutics, Inc. ALLO	$411 million
156. Assembly Biosciences, Inc. ASMB	$405 million
157. C4 Therapeutics, Inc. CCCC	$384 million
158. Avalo Therapeutics, Inc. AVTX	$379 million
159. Lyell Immunopharma, Inc. LYEL	$378 million
160. Autolus Therapeutics plc AUTL	$367 million
161. Fennec Pharmaceuticals Inc. FENC	$363 million
162. Orchestra BioMed Holdings, Inc. OBIO	$361 million
163. Opus Genetics, Inc. IRD	$355 million
164. ProKidney Corp. PROK	$339 million
165. Alector, Inc. ALEC	$338 million
166. Benitec Biopharma Inc. BNTC	$324 million
167. X4 Pharmaceuticals, Inc. XFOR	$321 million
168. Agenus Inc. AGEN	$314 million
169. Enanta Pharmaceuticals, Inc. ENTA	$310 million
170. Arcturus Therapeutics Holdings Inc. ARCT	$309 million
171. ARS Pharmaceuticals, Inc. SPRY	$303 million
172. Century Therapeutics, Inc. IPSC	$302 million
173. vTv Therapeutics Inc. VTVT	$299 million
174. Ocugen, Inc. OCGN	$297 million
175. SAB Biotherapeutics, Inc. SABS	$289 million
176. Fulcrum Therapeutics, Inc. FULC	$288 million
177. Inhibikase Therapeutics, Inc. IKT	$285 million
178. Q32 Bio Inc. QTTB	$267 million
179. Bicycle Therapeutics plc BCYC	$261 million
180. Lineage Cell Therapeutics, Inc. LCTX	$260 million
181. Fate Therapeutics, Inc. FATE	$250 million
182. Korro Bio, Inc. KRRO	$245 million
183. Immuneering Corporation IMRX	$244 million
184. Abeona Therapeutics Inc. ABEO	$241 million
185. Camp4 Therapeutics Corporation CAMP	$235 million
186. Vanda Pharmaceuticals Inc. VNDA	$235 million
187. AC Immune SA ACIU	$228 million
188. Evommune, Inc. EVMN	$219 million
189. InflaRx N.V. IFRX	$218 million
190. Protalix BioTherapeutics, Inc. PLX	$217 million
191. Sol-Gel Technologies Ltd. SLGL	$216 million
192. Keros Therapeutics, Inc. KROS	$215 million
193. Cartesian Therapeutics, Inc. RNAC	$206 million
194. Artiva Biotherapeutics, Inc. ARTV	$206 million
195. Upstream Bio, Inc. UPB	$203 million
196. Niagen Bioscience, Inc. NAGE	$200 million
197. ProQR Therapeutics N.V. PRQR	$199 million
198. Compugen Ltd. CGEN	$192 million
199. Invivyd, Inc. IVVD	$187 million
200. Entrada Therapeutics, Inc. TRDA	$182 million
201. Whitehawk Therapeutics, Inc. WHWK	$181 million
202. Sutro Biopharma, Inc. STRO	$165 million
203. Adagene Inc. ADAG	$162 million
204. MacroGenics, Inc. MGNX	$147 million
205. Cue Biopharma, Inc. CUE	$144 million
206. Coherus Oncology, Inc. CHRS	$131 million
207. Foghorn Therapeutics Inc. FHTX	$125 million
208. Armata Pharmaceuticals, Inc. ARMP	$117 million
209. Tonix Pharmaceuticals Holding Corp. TNXP	$98 million
210. Cellectis S.A. CLLS	$97 million
211. EyePoint, Inc. EYPT	$38 million

Download all 211 Biotechnology companies (CSV)

How has Biotechnology moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this industry is 69% ahead of S&P 500. Earnings across its companies fell 1% on average over the last four reported quarters.

Basing · +7 joined ~

Price up, without the fundamentals confirming. 70 of 286 companies ahead of S&P 500 by 5% or more over three months. 1 is 20% or more behind over a year while earnings grew 20% or more.

Not ahead of S&P 500 on the three-month view this week; 116 of the 280 companies in the industry index above their 200-day average (10 fewer than four weeks earlier); 70 of those 286 ahead of S&P 500 by 5% or more over three months (7 more than four weeks earlier); earnings rising at 158 of the 271 that report earnings.

Not ahead of S&P 500 yet, but 7 more stocks joined in four weeks, 63 → 70 of 286. Earnings mixed, 158 of 271 members have higher trailing twelve-month earnings than a year ago.

Biotechnology against S&P 500

Both lines start at 200 in the first week shown

Biotechnology 291
S&P 500 228

150200250300350291228

Biotechnology against S&P 500
Week ending	Biotechnology	S&P 500
14 Nov 2025	200	200
21 Nov 2025	205	196
28 Nov 2025	220	203
5 Dec 2025	223	204
12 Dec 2025	229	203
19 Dec 2025	228	203
26 Dec 2025	235	205
2 Jan 2026	228	203
9 Jan 2026	236	207
16 Jan 2026	238	206
23 Jan 2026	248	205
30 Jan 2026	238	206
6 Feb 2026	239	206
13 Feb 2026	238	203
20 Feb 2026	246	205
27 Feb 2026	256	204
6 Mar 2026	250	200
13 Mar 2026	247	197
20 Mar 2026	240	193
27 Mar 2026	237	189
3 Apr 2026	255	195
10 Apr 2026	259	202
17 Apr 2026	283	211
24 Apr 2026	270	213
1 May 2026	269	215
8 May 2026	278	220
15 May 2026	269	220
22 May 2026	269	222
29 May 2026	279	225
5 Jun 2026	258	220
12 Jun 2026	266	221
19 Jun 2026	278	222
26 Jun 2026	304	217
3 Jul 2026	317	222
10 Jul 2026	319	225
17 Jul 2026	310	221
24 Jul 2026	301	220
31 Jul 2026	296	222
7 Aug 2026	321	230
14 Aug 2026	326	231
21 Aug 2026	340	228
28 Aug 2026	334	229
4 Sep 2026	340	229
11 Sep 2026	319	227
18 Sep 2026	315	227
25 Sep 2026	302	230
2 Oct 2026	298	229
9 Oct 2026	296	232
16 Oct 2026	269	227
23 Oct 2026	282	226
30 Oct 2026	291	225
6 Nov 2026	291	228

Biotechnology against S&P 500

Both lines start at 200 in the first week shown, every 2nd week shown

Biotechnology 752
S&P 500 340

2004006008001,000752340

Biotechnology against S&P 500
Week ending	Biotechnology	S&P 500
17 Nov 2023	200	200
24 Nov 2023	202	202
8 Dec 2023	219	204
22 Dec 2023	244	210
5 Jan 2024	248	208
19 Jan 2024	245	214
2 Feb 2024	258	219
16 Feb 2024	286	222
1 Mar 2024	315	228
15 Mar 2024	302	226
29 Mar 2024	318	232
12 Apr 2024	306	227
26 Apr 2024	288	226
10 May 2024	304	231
24 May 2024	301	235
7 Jun 2024	304	237
21 Jun 2024	303	242
5 Jul 2024	299	246
19 Jul 2024	326	244
2 Aug 2024	321	236
16 Aug 2024	319	246
30 Aug 2024	335	250
13 Sep 2024	343	249
27 Sep 2024	338	254
11 Oct 2024	341	257
25 Oct 2024	352	257
8 Nov 2024	381	265
22 Nov 2024	354	264
6 Dec 2024	365	270
20 Dec 2024	341	262
3 Jan 2025	353	263
17 Jan 2025	325	265
31 Jan 2025	342	267
14 Feb 2025	343	271
28 Feb 2025	319	264
14 Mar 2025	314	250
28 Mar 2025	304	247
11 Apr 2025	265	237
25 Apr 2025	302	244
9 May 2025	288	250
23 May 2025	299	257
6 Jun 2025	335	266
20 Jun 2025	321	264
4 Jul 2025	337	277
18 Jul 2025	355	278
1 Aug 2025	358	276
15 Aug 2025	391	285
29 Aug 2025	397	286
12 Sep 2025	417	292
26 Sep 2025	450	294
10 Oct 2025	488	290
24 Oct 2025	514	300
7 Nov 2025	495	298
21 Nov 2025	528	292
5 Dec 2025	575	304
19 Dec 2025	588	302
2 Jan 2026	588	303
16 Jan 2026	613	307
30 Jan 2026	615	307
13 Feb 2026	613	302
27 Feb 2026	660	304
13 Mar 2026	638	294
27 Mar 2026	612	281
10 Apr 2026	669	301
24 Apr 2026	697	317
8 May 2026	718	327
22 May 2026	695	331
5 Jun 2026	665	327
19 Jun 2026	717	331
3 Jul 2026	818	330
17 Jul 2026	799	330
31 Jul 2026	765	331
14 Aug 2026	840	344
28 Aug 2026	862	341
11 Sep 2026	824	339
25 Sep 2026	780	342
9 Oct 2026	764	345
23 Oct 2026	726	337
6 Nov 2026	752	340

Biotechnology against S&P 500

Both lines start at 200 in the first week shown, every 4th week shown

Biotechnology 581
S&P 500 327

0200400600800581327

Biotechnology against S&P 500
Week ending	Biotechnology	S&P 500
19 Nov 2021	200	200
10 Dec 2021	184	201
7 Jan 2022	172	199
4 Feb 2022	151	191
4 Mar 2022	145	184
1 Apr 2022	159	193
29 Apr 2022	129	176
27 May 2022	120	177
24 Jun 2022	133	166
22 Jul 2022	147	169
19 Aug 2022	161	180
16 Sep 2022	155	164
14 Oct 2022	143	153
11 Nov 2022	159	170
9 Dec 2022	153	168
6 Jan 2023	164	166
3 Feb 2023	183	176
3 Mar 2023	165	172
31 Mar 2023	153	175
28 Apr 2023	161	177
26 May 2023	167	179
23 Jun 2023	174	185
21 Jul 2023	180	193
18 Aug 2023	167	186
15 Sep 2023	169	189
13 Oct 2023	150	184
10 Nov 2023	144	188
8 Dec 2023	170	196
5 Jan 2024	191	200
2 Feb 2024	200	211
1 Mar 2024	243	219
29 Mar 2024	246	223
26 Apr 2024	223	217
24 May 2024	233	226
21 Jun 2024	234	232
19 Jul 2024	252	234
16 Aug 2024	247	236
13 Sep 2024	265	240
11 Oct 2024	264	247
8 Nov 2024	294	255
6 Dec 2024	282	259
3 Jan 2025	273	252
31 Jan 2025	264	257
28 Feb 2025	246	253
28 Mar 2025	235	237
25 Apr 2025	233	235
23 May 2025	231	247
20 Jun 2025	248	253
18 Jul 2025	275	268
15 Aug 2025	302	274
12 Sep 2025	322	280
10 Oct 2025	377	279
7 Nov 2025	382	286
5 Dec 2025	445	292
2 Jan 2026	455	291
30 Jan 2026	475	295
27 Feb 2026	510	293
27 Mar 2026	473	270
24 Apr 2026	539	305
22 May 2026	537	318
19 Jun 2026	554	319
17 Jul 2026	617	317
14 Aug 2026	650	331
11 Sep 2026	637	326
9 Oct 2026	590	332
6 Nov 2026	581	327

Earnings, each company rebased to 100, the sector takes the median

Latest quarter April to June 2026: 0.0, from 29 companies

0501000.0

Earnings, each company rebased to 100, the sector takes the median
Quarter	Median earnings index
Jan 2022	100.0 (28 companies)
Apr 2022	89.7 (29 companies)
Jul 2022	88.1 (29 companies)
Oct 2022	48.7 (29 companies)
Jan 2023	34.2 (30 companies)
Apr 2023	16.2 (31 companies)
Jul 2023	0.0 (31 companies)
Oct 2023	0.0 (31 companies)
Jan 2024	0.0 (31 companies)
Apr 2024	0.0 (31 companies)
Jul 2024	0.0 (31 companies)
Oct 2024	0.0 (31 companies)
Jan 2025	0.0 (31 companies)
Apr 2025	0.0 (29 companies)
Jul 2025	0.0 (29 companies)
Oct 2025	0.0 (30 companies)
Jan 2026	0.0 (30 companies)
Apr 2026	0.0 (29 companies)

Both lines start at 200 in the same week, so the gap between them tells the story: the industry line is an equal-weighted index of its 286 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the industry taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Is Biotechnology outperforming S&P 500?

Biotechnology has done better than the S&P 500 by 55.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 16.7%. Moderna, Inc. is the strongest against the sector itself at +167.3%.

+16.7%Sector vs S&P 500 · 13 weeks

+55.3%Sector vs S&P 500 · 52 weeks

21 of 30Stocks leading S&P 500

10 of 30Stocks leading the sector

What is the bottom line on Biotechnology?

Biotechnology has done better than the S&P 500 by 55.3% over 52 weeks and by 16.7% over 13 weeks. 21 of 30 companies we track are beating the S&P 500 on relative strength (how a share price has done against the index over recent months) (3 have no relative-strength reading yet), and 10 of the 27 with a long enough price history are ahead of the industry itself.

How does each Biotechnology stock score?

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Growth & earnings · 35% Capital efficiency · 25% Valuation · 20% Relative strength · 20%

Exelixis, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 81.1% evidence confidence.

Genmab A/S scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

1Exelixis, Inc.EXEL · breaking out · favourable · 81% evidence76.0out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 22.9/35 · Revenue 9.3% · PAT 42.8% · OPM change 1.9 pp · 83% evidenceCapital efficiency 21.0/25 · ROCE 46.5% · OPM 39.5% · 76% evidenceValuation 14.4/20 · P/E 15.9× · PEG 0.3 · 65% evidenceRelative strength 17.7/20 · RS sector 10.5% · RS bench 37% · 1Y 78.3% · 100% evidence · 8 of 12 weeks aheadExact sum: 22.9 + 21 + 14.4 + 17.7 = 76 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
2Halozyme Therapeutics, Inc.HALO · leader · favourable · 81% evidence71.1out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 17.1/35 · Revenue 41.1% · PAT −25.9% · OPM change −2.4 pp · 83% evidenceCapital efficiency 21.0/25 · ROCE 42.3% · OPM 59.8% · 76% evidenceValuation 14.4/20 · P/E 22.4× · PEG 0.25 · 65% evidenceRelative strength 18.6/20 · RS sector 22.6% · RS bench 50.7% · 1Y 91% · 100% evidence · 12 of 12 weeks aheadExact sum: 17.1 + 21 + 14.4 + 18.6 = 71.1 · What this means: Relative strength against the index is 50.7%, and revenue and profit growth are weak.
3Caris Life Sciences, Inc.CAI · leader · favourable · 64% evidence65.7out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 23.7/35 · Revenue 85.4% · PAT — · OPM change 20.1 pp · 62% evidenceCapital efficiency 13.1/25 · ROCE 14.8% · OPM 10.2% · 76% evidenceValuation 11.2/20 · P/E −14.2× · PEG — · 15% evidenceRelative strength 17.7/20 · RS sector 10.2% · RS bench 37.4% · 1Y 29.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 23.7 + 13.1 + 11.2 + 17.7 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
4Incyte CorporationINCY · turning · mixed, leaning good · 71% evidence64.3out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 26.4/35 · Revenue 26.9% · PAT 85.3% · OPM change 16.3 pp · 83% evidenceCapital efficiency 20.6/25 · ROCE 28.1% · OPM 41.9% · 76% evidenceValuation 10.7/20 · P/E 14× · PEG — · 15% evidenceRelative strength 6.6/20 · RS sector −13.6% · RS bench 7.7% · 1Y 15.9% · 100% evidence · 5 of 12 weeks aheadExact sum: 26.4 + 20.6 + 10.7 + 6.6 = 64.3 · What this means: Earnings are strong; relative strength in its sector is −13.6% and the one-year return is 15.9%.
5Genmab A/SGMAB · leader · mixed, leaning good · 81% evidence60.8out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 10.7/35 · Revenue 18.2% · PAT −39.3% · OPM change −3.7 pp · 83% evidenceCapital efficiency 15.7/25 · ROCE 11.7% · OPM 35.2% · 76% evidenceValuation 14.9/20 · P/E 21.4× · PEG 0.21 · 65% evidenceRelative strength 19.5/20 · RS sector 32.8% · RS bench 65.2% · 1Y 92.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 10.7 + 15.7 + 14.9 + 19.5 = 60.8 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak.
6argenx SEARGX · turning · mixed, leaning good · 85% evidence58.8out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 24.7/35 · Revenue 60.6% · PAT 22.4% · OPM change 5.9 pp · 95% evidenceCapital efficiency 16.9/25 · ROCE 18.9% · OPM 36.3% · 76% evidenceValuation 9.8/20 · P/E 32× · PEG 1.39 · 65% evidenceRelative strength 7.4/20 · RS sector −18.3% · RS bench 2.3% · 1Y 9% · 100% evidence · 6 of 12 weeks aheadExact sum: 24.7 + 16.9 + 9.8 + 7.4 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
7Kymera Therapeutics, Inc.KYMR · turning · mixed, leaning good · 61% evidence57.6out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 23.7/35 · Revenue 100% · PAT — · OPM change 620.5 pp · 62% evidenceCapital efficiency 6.8/25 · ROCE −22% · OPM −116.3% · 76% evidenceValuation 10.0/20 · P/E — · PEG — · 0% evidenceRelative strength 17.1/20 · RS sector 12.3% · RS bench 38.4% · 1Y 132.3% · 100% evidence · 7 of 12 weeks aheadExact sum: 23.7 + 6.8 + 10 + 17.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
8Vertex Pharmaceuticals IncorporatedVRTX · breaking out · mixed, leaning good · 81% evidence56.1out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 15.9/35 · Revenue 10.2% · PAT 21.1% · OPM change −0.8 pp · 83% evidenceCapital efficiency 19.6/25 · ROCE 20.9% · OPM 38.1% · 76% evidenceValuation 10.9/20 · P/E 28.6× · PEG 1.25 · 65% evidenceRelative strength 9.7/20 · RS sector −13% · RS bench 8.5% · 1Y 34.1% · 100% evidence · 8 of 12 weeks aheadExact sum: 15.9 + 19.6 + 10.9 + 9.7 = 56.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
9Spyre Therapeutics, Inc.SYRE · quiet · provisional · 56% evidence55.8out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 23.3/35 · Revenue — · PAT — · OPM change 999.3 pp · 52% evidenceCapital efficiency 8.6/25 · ROCE −24.5% · OPM — · 61% evidenceValuation 10.9/20 · P/E −8.2× · PEG — · 15% evidenceRelative strength 13.0/20 · RS sector 18.5% · RS bench 43.8% · 1Y 339.8% · 100% evidence · 4 of 12 weeks aheadExact sum: 23.3 + 8.6 + 10.9 + 13 = 55.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
10BeOne Medicines AGONC · leader · mixed, leaning good · 64% evidence54.9out of 100GrowthCapitalValuationRelative
How the score adds up
Growth & earnings 22.3/35 · Revenue 34.3% · PAT — · OPM change 12.4 pp · 62% evidenceCapital efficiency 13.4/25 · ROCE 13.1% · OPM 19.1% · 76% evidenceValuation 9.1/20 · P/E 48.3× · PEG — · 15% evidenceRelative strength 10.1/20 · RS sector −13.3% · RS bench 8.4% · 1Y 17.7% · 100% evidence · 12 of 12 weeks aheadExact sum: 22.3 + 13.4 + 9.1 + 10.1 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
11Moderna, Inc.MRNA · leader · mixed, leaning good · 64% evidence54.7out of 100GrowthCapitalValuationRelative
12Jazz Pharmaceuticals plcJAZZ · quiet · mixed, leaning good · 74% evidence53.6out of 100GrowthCapitalValuationRelative
13Regeneron Pharmaceuticals, Inc.REGN · leader · mixed, leaning good · 81% evidence51.9out of 100GrowthCapitalValuationRelative
14Alnylam Pharmaceuticals, Inc.ALNY · quiet · mixed, leaning good · 64% evidence51.1out of 100GrowthCapitalValuationRelative
15Royalty Pharma plcRPRX · turning · mixed, leaning good · 81% evidence50.9out of 100GrowthCapitalValuationRelative
16ImmunityBio, Inc.IBRX · breaking out · mixed, leaning weak · 61% evidence49.5out of 100GrowthCapitalValuationRelative
17Protagonist Therapeutics, Inc.PTGX · fading · mixed, leaning weak · 74% evidence49.2out of 100GrowthCapitalValuationRelative
18Bio-Techne CorporationTECH · turning · mixed, leaning weak · 74% evidence42.2out of 100GrowthCapitalValuationRelative
19Summit Therapeutics Inc.SMMT · breaking out · provisional · 53% evidence39.7out of 100GrowthCapitalValuationRelative
20Revolution Medicines, Inc.RVMD · quiet · provisional · 53% evidence39.5out of 100GrowthCapitalValuationRelative
21Roivant Sciences Ltd.ROIV · turning · provisional · 60% evidence38.0out of 100GrowthCapitalValuationRelative
22Madrigal Pharmaceuticals, Inc.MDGL · quiet · mixed, leaning weak · 61% evidence36.4out of 100GrowthCapitalValuationRelative
23Insmed IncorporatedINSM · basing · mixed, leaning weak · 61% evidence35.2out of 100GrowthCapitalValuationRelative
24BridgeBio Pharma, Inc.BBIO · quiet · weak · 61% evidence34.8out of 100GrowthCapitalValuationRelative
25BioNTech SEBNTX · quiet · weak · 64% evidence32.4out of 100GrowthCapitalValuationRelative
26BioMarin Pharmaceutical Inc.BMRN · quiet · weak · 81% evidence26.7out of 100GrowthCapitalValuationRelative

Ranked last: too little evidence (4 companies)

Under 60% of the evidence behind these scores is available, so they rank after every company above, whatever the score.

27Ascendis Pharma A/SASND · turning · provisional · 44% evidence63.0out of 100GrowthCapitalValuationRelative
28Apogee Therapeutics, Inc.APGE · provisional · 27% evidence46.7out of 100GrowthCapitalValuationRelative
29Nuvalent, Inc.NUVL · provisional · 20% evidence40.9out of 100GrowthCapitalValuationRelative
30Vaxcyte, Inc.PCVX · breaking out · provisional · 47% evidence38.2out of 100GrowthCapitalValuationRelative

How this score is built, and what the marks mean

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

How have Biotechnology share prices moved?

Moderna, Inc. has the strongest one-year price move in Biotechnology at +953.3%. It also leads on relative strength against the S&P 500, at +212.6%. 21 of 30 companies we track are ahead of the index on that measure (3 have no relative-strength reading yet). Every line covers 314 weekly closes through 4 November 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs S&P 500: How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Biotechnology itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Price of the 5 strongest one-year movers, each started at 100

52 weekly closes

Moderna, Inc. 1,044
Spyre Therapeutics, Inc. 421
ImmunityBio, Inc. 429
Revolution Medicines, 294
Kymera Therapeutics, 210
S&P 500 114

02505007501,0001,2501,044

Price of the 5 strongest one-year movers, each started at 100
Week ending	Moderna, Inc.	Spyre Therapeutics, Inc.	ImmunityBio, Inc.	Revolution Medicines,	Kymera Therapeutics,	S&P 500
14 Nov 2025	100	100	100	100	100	100
21 Nov 2025	96	103	100	105	102	98
28 Nov 2025	105	128	114	115	105	102
5 Dec 2025	112	142	110	118	103	102
12 Dec 2025	119	143	114	117	138	102
19 Dec 2025	137	142	100	116	129	101
26 Dec 2025	126	140	103	119	125	103
2 Jan 2026	125	130	97	117	112	102
9 Jan 2026	139	130	112	175	115	103
16 Jan 2026	169	141	265	178	107	103
23 Jan 2026	197	136	310	174	108	103
30 Jan 2026	178	136	301	143	112	103
6 Feb 2026	166	149	291	144	123	103
13 Feb 2026	171	156	286	142	127	102
20 Feb 2026	201	184	418	150	135	103
27 Feb 2026	216	183	470	151	141	102
6 Mar 2026	212	171	417	145	129	100
13 Mar 2026	212	170	403	140	122	99
20 Mar 2026	207	176	407	141	120	97
27 Mar 2026	200	201	355	137	120	94
3 Apr 2026	199	203	351	146	132	98
10 Apr 2026	206	218	350	142	131	101
17 Apr 2026	217	311	370	219	135	106
24 Apr 2026	205	297	358	200	131	106
1 May 2026	183	295	342	206	124	107
8 May 2026	219	319	409	209	133	110
15 May 2026	198	319	383	215	127	110
22 May 2026	189	315	347	224	122	111
29 May 2026	191	313	362	232	125	113
5 Jun 2026	192	313	333	220	114	110
12 Jun 2026	202	344	341	227	133	110
19 Jun 2026	258	376	354	241	139	111
26 Jun 2026	272	374	419	269	167	109
3 Jul 2026	322	369	454	279	175	111
10 Jul 2026	276	416	395	276	184	112
17 Jul 2026	250	427	369	275	178	111
24 Jul 2026	218	435	341	279	170	110
31 Jul 2026	221	418	345	277	159	111
7 Aug 2026	239	446	367	303	166	115
14 Aug 2026	256	441	364	301	181	116
21 Aug 2026	586	453	375	309	185	114
28 Aug 2026	557	385	387	307	182	115
4 Sep 2026	588	379	389	310	181	115
11 Sep 2026	581	386	380	301	177	114
18 Sep 2026	622	384	408	282	181	113
25 Sep 2026	803	365	406	303	172	115
2 Oct 2026	767	397	495	305	165	115
9 Oct 2026	908	365	505	280	173	116
16 Oct 2026	880	340	441	263	161	114
23 Oct 2026	808	384	395	276	171	113
30 Oct 2026	895	411	399	282	195	113
6 Nov 2026	1,044	421	429	294	210	114

Price of the 5 strongest one-year movers, each started at 100

156 weekly closes, every 2nd shown

Moderna, Inc. 338
Spyre Therapeutics, Inc. 966
ImmunityBio, Inc. 216
Revolution Medicines, 935
Kymera Therapeutics, 701
S&P 500 170

02505007501,0001,250338

Price of the 5 strongest one-year movers, each started at 100
Week ending	Moderna, Inc.	Spyre Therapeutics, Inc.	ImmunityBio, Inc.	Revolution Medicines,	Kymera Therapeutics,	S&P 500
17 Nov 2023	100	100	100	100	100	100
24 Nov 2023	103	108	100	101	103	101
8 Dec 2023	105	191	83	115	118	102
22 Dec 2023	124	177	107	128	132	105
5 Jan 2024	145	217	107	133	140	104
19 Jan 2024	130	235	87	126	142	107
2 Feb 2024	128	251	100	133	170	110
16 Feb 2024	116	227	117	138	199	111
1 Mar 2024	124	292	114	140	224	114
15 Mar 2024	136	443	124	149	209	113
29 Mar 2024	139	370	130	151	207	116
12 Apr 2024	138	366	123	169	183	113
26 Apr 2024	141	327	178	169	172	113
10 May 2024	154	360	196	175	195	116
24 May 2024	218	322	158	178	175	117
7 Jun 2024	198	329	147	189	170	119
21 Jun 2024	175	235	175	179	165	121
5 Jul 2024	155	249	154	176	156	123
19 Jul 2024	159	288	140	216	222	122
2 Aug 2024	113	256	113	206	216	118
16 Aug 2024	114	254	97	201	225	123
30 Aug 2024	101	281	95	200	249	125
13 Sep 2024	89	286	87	205	237	125
27 Sep 2024	86	278	95	207	251	127
11 Oct 2024	76	280	88	237	232	129
25 Oct 2024	70	340	129	218	247	129
8 Nov 2024	61	386	135	283	262	133
22 Nov 2024	54	270	123	266	232	132
6 Dec 2024	58	264	120	225	240	135
20 Dec 2024	52	233	63	207	209	131
3 Jan 2025	55	238	68	207	214	131
17 Jan 2025	45	201	71	189	209	133
31 Jan 2025	52	224	83	201	204	134
14 Feb 2025	43	224	87	191	190	135
28 Feb 2025	41	192	80	191	161	132
14 Mar 2025	45	176	69	183	177	125
28 Mar 2025	41	175	76	175	152	123
11 Apr 2025	34	119	64	168	124	118
25 Apr 2025	36	138	63	182	171	122
9 May 2025	32	138	50	190	155	125
23 May 2025	34	146	61	187	152	129
6 Jun 2025	36	166	76	193	245	133
20 Jun 2025	34	146	69	186	236	132
4 Jul 2025	40	154	66	178	231	139
18 Jul 2025	41	159	66	180	238	139
1 Aug 2025	36	159	57	172	221	138
15 Aug 2025	37	165	62	170	219	143
29 Aug 2025	32	161	57	178	212	143
12 Sep 2025	31	153	63	218	242	146
26 Sep 2025	32	158	61	206	290	147
10 Oct 2025	35	187	57	226	294	145
24 Oct 2025	35	228	60	255	301	150
7 Nov 2025	32	220	51	286	302	149
21 Nov 2025	31	237	50	332	340	146
5 Dec 2025	36	326	55	373	343	152
19 Dec 2025	44	326	50	369	432	151
2 Jan 2026	40	298	49	371	375	152
16 Jan 2026	55	324	133	564	358	153
30 Jan 2026	58	312	151	455	374	154
13 Feb 2026	55	357	144	452	424	151
27 Feb 2026	70	420	236	478	470	152
13 Mar 2026	69	389	203	445	407	147
27 Mar 2026	65	462	178	434	402	141
10 Apr 2026	67	500	176	452	438	151
24 Apr 2026	66	680	180	634	437	158
8 May 2026	71	732	206	665	443	164
22 May 2026	61	722	174	711	406	165
5 Jun 2026	62	719	167	700	382	164
19 Jun 2026	84	862	178	764	465	166
3 Jul 2026	104	845	228	887	584	165
17 Jul 2026	81	978	186	873	596	165
31 Jul 2026	72	959	173	879	532	166
14 Aug 2026	83	1,011	183	955	604	172
28 Aug 2026	181	882	194	975	608	171
11 Sep 2026	188	884	191	955	592	170
25 Sep 2026	260	836	204	961	576	171
9 Oct 2026	294	836	254	890	579	173
23 Oct 2026	262	881	199	877	570	169
6 Nov 2026	338	966	216	935	701	170

Price of the 5 strongest one-year movers, each started at 100

260 weekly closes, every 4th shown

Moderna, Inc. 98
Spyre Therapeutics, Inc. 59
ImmunityBio, Inc. 139
Revolution Medicines, 670
Kymera Therapeutics, 222
S&P 500 164

020040060080098

Price of the 5 strongest one-year movers, each started at 100
Week ending	Moderna, Inc.	Spyre Therapeutics, Inc.	ImmunityBio, Inc.	Revolution Medicines,	Kymera Therapeutics,	S&P 500
19 Nov 2021	100	100	100	100	100	100
10 Dec 2021	98	56	91	83	86	100
7 Jan 2022	81	64	97	77	90	99
4 Feb 2022	62	64	84	72	65	96
4 Mar 2022	52	34	95	58	58	92
1 Apr 2022	67	39	90	86	68	97
29 Apr 2022	51	22	57	67	51	88
27 May 2022	56	24	61	57	25	89
24 Jun 2022	55	9	65	63	33	83
22 Jul 2022	62	6	68	75	35	84
19 Aug 2022	55	14	62	76	52	90
16 Sep 2022	52	7	94	68	42	82
14 Oct 2022	51	7	77	62	36	76
11 Nov 2022	65	21	91	75	50	85
9 Dec 2022	67	6	96	80	42	84
6 Jan 2023	68	8	67	75	44	83
3 Feb 2023	66	8	67	87	60	88
3 Mar 2023	54	6	31	86	53	86
31 Mar 2023	58	4	28	73	48	87
28 Apr 2023	50	3	44	79	51	89
26 May 2023	48	2	40	86	48	90
23 Jun 2023	45	6	42	86	37	92
21 Jul 2023	48	9	44	90	35	96
18 Aug 2023	39	7	28	100	32	93
15 Sep 2023	43	8	28	107	31	95
13 Oct 2023	37	8	20	101	21	92
10 Nov 2023	27	6	48	66	24	94
8 Dec 2023	30	12	53	83	37	98
5 Jan 2024	42	13	69	95	44	100
2 Feb 2024	37	15	64	96	54	105
1 Mar 2024	36	18	73	100	71	109
29 Mar 2024	40	23	84	108	65	112
26 Apr 2024	41	20	114	121	54	108
24 May 2024	63	20	101	128	55	113
21 Jun 2024	51	14	113	128	52	116
19 Jul 2024	46	18	90	155	70	117
16 Aug 2024	33	16	62	144	71	118
13 Sep 2024	26	18	56	147	75	120
11 Oct 2024	22	17	57	170	73	124
8 Nov 2024	18	24	87	203	83	128
6 Dec 2024	17	16	77	162	76	130
3 Jan 2025	16	15	44	148	68	126
31 Jan 2025	15	14	54	144	64	128
28 Feb 2025	12	12	51	137	51	127
28 Mar 2025	12	11	49	126	48	119
25 Apr 2025	10	9	41	130	54	117
23 May 2025	10	9	39	134	48	124
20 Jun 2025	10	9	45	133	75	127
18 Jul 2025	12	10	43	129	75	134
15 Aug 2025	11	10	40	122	69	137
12 Sep 2025	9	9	40	157	76	140
10 Oct 2025	10	12	37	162	93	139
7 Nov 2025	9	14	33	205	95	143
5 Dec 2025	11	20	36	268	108	146
2 Jan 2026	12	18	31	266	118	146
30 Jan 2026	17	19	97	326	118	148
27 Feb 2026	20	26	152	343	149	146
27 Mar 2026	19	28	115	311	127	135
24 Apr 2026	19	42	116	455	138	152
22 May 2026	18	44	112	509	128	159
19 Jun 2026	24	53	115	548	147	159
17 Jul 2026	23	60	119	626	188	159
14 Aug 2026	24	62	118	685	191	166
11 Sep 2026	55	54	123	685	187	163
9 Oct 2026	85	51	164	638	183	166
6 Nov 2026	98	59	139	670	222	164

The companies with the strongest one-year price moves are drawn. The S&P 500 line is dashed.

Biggest one-year moves

1Moderna, Inc.MRNA · $103.2B+953.3%1 year
2Spyre Therapeutics, Inc.SYRE · $9.3B+339.8%1 year
3ImmunityBio, Inc.IBRX · $9.5B+319.2%1 year
4Revolution Medicines, Inc.RVMD · $42.7B+226.7%1 year
5Kymera Therapeutics, Inc.KYMR · $11.6B+132.3%1 year

Strongest against S&P 500

1Moderna, Inc.MRNA · $103.2B+212.6%vs S&P 500
2Genmab A/SGMAB · $31.9B+65.2%vs S&P 500
3Halozyme Therapeutics, Inc.HALO · $14.8B+50.7%vs S&P 500
4Spyre Therapeutics, Inc.SYRE · $9.3B+43.8%vs S&P 500
5Kymera Therapeutics, Inc.KYMR · $11.6B+38.4%vs S&P 500

Strongest against the sector itself

1Moderna, Inc.MRNA · $103.2B+167.3%vs sector
2Genmab A/SGMAB · $31.9B+32.8%vs sector
3Halozyme Therapeutics, Inc.HALO · $14.8B+22.6%vs sector
4Spyre Therapeutics, Inc.SYRE · $9.3B+18.5%vs sector
5Kymera Therapeutics, Inc.KYMR · $11.6B+12.3%vs sector

Which Biotechnology companies have the most revenue, and which grow fastest?

Regeneron Pharmaceuticals, Inc. has the highest Revenue among the 30 Biotechnology companies compared here, at $15,534 million. Vertex Pharmaceuticals Incorporated is next at $12,587 million. Ascendis Pharma A/S has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies. Its Revenue series carries 19 reported observations across the 20-quarter window.

What the numbers say: Regeneron Pharmaceuticals, Inc. is the largest at $15,534 million, 23.4% ahead of Vertex Pharmaceuticals Incorporated. Ascendis Pharma A/S's growth is capped at 100% on the scoring scale; the full change over the last 12 months is 113.4% from a $1,048 million base, with 19 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

Regeneron Pharmaceuticals, Inc. · $15,534 millionLeader

23.4% versus #2 · Vertex Pharmaceuticals IncorporatedGap

7/8 recent comparable periodsPersistence

24/30 companies · 451 observationsCoverage

What this means: Regeneron Pharmaceuticals, Inc. is the size to compare against; Ascendis Pharma A/S is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Regeneron Pharmaceuticals, Inc.'s growth falls below Ascendis Pharma A/S's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue, by reported quarter

Regeneron Pharmaceuticals, Inc. $4.3B
Vertex Pharmaceuticals Incorporated $3.3B
BeOne Medicines AG $1.7B
argenx SE $1.8B
Incyte Corporation $1.7B

$0M$2.0B$4.0B$6.0B$4.3B

Revenue, by reported quarter
Quarter	Regeneron Pharmaceuticals, Inc.	Vertex Pharmaceuticals Incorporated	BeOne Medicines AG	argenx SE	Incyte Corporation
Dec 2021	$5.0B	$2.1B	$214M	$34M	$863M
Mar 2022	$3.0B	$2.1B	$307M	$31M	$733M
Jun 2022	$2.9B	$2.2B	$342M	$85M	$911M
Sep 2022	$2.9B	$2.3B	$388M	$146M	$823M
Dec 2022	$3.4B	$2.3B	$380M	$178M	$927M
Mar 2023	$3.2B	$2.4B	$448M	$230M	$809M
Jun 2023	$3.2B	$2.5B	$595M	$281M	$955M
Sep 2023	$3.4B	$2.5B	$721M	$340M	$919M
Dec 2023	$3.4B	$2.5B	$643M	$418M	$1.0B
Mar 2024	$3.1B	$2.7B	$752M	$413M	$881M
Jun 2024	$3.5B	$2.6B	$929M	$489M	$1.0B
Sep 2024	$3.7B	$2.8B	$1.0B	$589M	$1.1B
Dec 2024	$3.8B	$2.9B	$1.1B	$757M	$1.2B
Mar 2025	$3.0B	$2.8B	$1.1B	$807M	$1.1B
Jun 2025	$3.7B	$3.0B	$1.3B	$968M	$1.2B
Sep 2025	$3.8B	$3.1B	$1.4B	$1.2B	$1.4B
Dec 2025	$3.9B	$3.2B	$1.5B	$1.3B	$1.5B
Mar 2026	$3.6B	$3.0B	$1.5B	$1.3B	$1.3B
Jun 2026	$4.3B	$3.3B	$1.7B	$1.5B	$1.7B
Sep 2026	—	—	—	$1.8B	—

Revenue growth, by reported quarter

Regeneron Pharmaceuticals, Inc. 17%
Vertex Pharmaceuticals Incorporated 12%
BeOne Medicines AG 30%
argenx SE 52%
Incyte Corporation 38%

−100%0%100%200%17%

Revenue growth, by reported quarter
Quarter	Regeneron Pharmaceuticals, Inc.	Vertex Pharmaceuticals Incorporated	BeOne Medicines AG	argenx SE	Incyte Corporation
Dec 2021	—	—	—	—	—
Mar 2022	—	—	—	—	—
Jun 2022	−44%	22%	128%	−73%	29%
Sep 2022	−15%	18%	88%	1,986%	1.2%
Dec 2022	−31%	11%	78%	424%	7.4%
Mar 2023	6.6%	13%	46%	642%	10%
Jun 2023	11%	14%	74%	231%	4.8%
Sep 2023	15%	6.4%	86%	133%	12%
Dec 2023	0.6%	9.3%	69%	135%	9.3%
Mar 2024	−0.5%	13%	68%	80%	8.9%
Jun 2024	12%	6.1%	56%	74%	9.3%
Sep 2024	11%	12%	39%	73%	24%
Dec 2024	10%	16%	75%	81%	16%
Mar 2025	−3.7%	2.9%	49%	95%	20%
Jun 2025	3.6%	12%	42%	98%	16%
Sep 2025	0.9%	11%	41%	95%	20%
Dec 2025	2.5%	9.6%	33%	73%	28%
Mar 2026	19%	7.8%	35%	63%	21%
Jun 2026	17%	12%	30%	59%	38%
Sep 2026	—	—	—	52%	—

24 of 30 companies report revenue, 24 of 30 revenue growth. On every company-comparison chart on this page the five leaders are drawn, level and change on separate charts, and a missing report breaks the line rather than being invented. The revenue growth chart is drawn inside its usual range; a quarter far outside it (often a first quarter after listing or a near-zero base) is marked with an arrow at the edge, with its exact value in the hover card and the table.

Revenue · largest

1Regeneron Pharmaceuticals, Inc.REGN$15.5B
2Vertex Pharmaceuticals IncorporatedVRTX$12.6B
3BeOne Medicines AGONC$6.1B
4argenx SEARGX$5.9B
5Incyte CorporationINCY$5.8B

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue, every company
Company	Revenue	Revenue growth	Reported
Regeneron Pharmaceuticals, Inc. REGN	$4.3B	17%	Jun 2026
Vertex Pharmaceuticals Incorporated VRTX	$3.3B	12%	Jun 2026
argenx SE ARGX	$1.8B	52%	Sep 2026
BeOne Medicines AG ONC	$1.7B	30%	Jun 2026
Incyte Corporation INCY	$1.7B	38%	Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY	$1.3B	67%	Jun 2026
Jazz Pharmaceuticals plc JAZZ	$1.2B	15%	Jun 2026
Genmab A/S GMAB	$1.2B	25%	Jun 2026
BioMarin Pharmaceutical Inc. BMRN	$990M	20%	Jun 2026
Royalty Pharma plc RPRX	$674M	16%	Jun 2026
Exelixis, Inc. EXEL	$629M	11%	Jun 2026
Halozyme Therapeutics, Inc. HALO	$481M	48%	Jun 2026
Insmed Incorporated INSM	$425M	297%	Jun 2026
Madrigal Pharmaceuticals, Inc. MDGL	$364M	71%	Jun 2026
Ascendis Pharma A/S ASND	$339M	115%	Jun 2026
Bio-Techne Corporation TECH	$321M	1.3%	Jun 2026
Caris Life Sciences, Inc. CAI	$264M	46%	Jun 2026
BridgeBio Pharma, Inc. BBIO	$244M	120%	Jun 2026
Protagonist Therapeutics, Inc. PTGX	$213M	3,450%	Jun 2026
Moderna, Inc. MRNA	$145M	2.1%	Jun 2026
BioNTech SE BNTX	$106M	−59%	Jun 2026
Kymera Therapeutics, Inc. KYMR	$65M	491%	Jun 2026
ImmunityBio, Inc. IBRX	$51M	96%	Jun 2026
Revolution Medicines, Inc. RVMD	$1M	−93%	Jun 2026
Roivant Sciences Ltd. ROIV	$1M	−50%	Jun 2026
Spyre Therapeutics, Inc. SYRE	$1M	0.0%	Jun 2026
Summit Therapeutics Inc. SMMT	$0M	−100%	Jun 2026

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

What to watch

Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.

Which Biotechnology companies keep the most from each $100 of sales?

Protagonist Therapeutics, Inc. has the highest OPM among the 30 Biotechnology companies compared here, at 74.4%. Ascendis Pharma A/S is next at 65%. Spyre Therapeutics, Inc. has the highest Margin change at +999.3 percentage points, so level and change sit with different companies. 23 of 30 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Protagonist Therapeutics, Inc. leads opm at 74.4%; Spyre Therapeutics, Inc. leads margin change at +999.3 percentage points.

Protagonist Therapeutics, Inc. · 74.4%Leader

14.5% versus #2 · Ascendis Pharma A/SGap

4/8 recent comparable periodsPersistence

23/30 companies · 387 observationsCoverage

What this means: Protagonist Therapeutics, Inc. sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM, by reported quarter

Protagonist Therapeutics, Inc. 74%
Ascendis Pharma A/S 65%
Halozyme Therapeutics, Inc. 60%
Incyte Corporation 42%
Exelixis, Inc. 40%

−1,000%−500%0%500%74%

OPM, by reported quarter
Quarter	Protagonist Therapeutics, Inc.	Ascendis Pharma A/S	Halozyme Therapeutics, Inc.	Incyte Corporation	Exelixis, Inc.
Dec 2021	−430%	—	55%	13%	26%
Mar 2022	−82%	—	65%	17%	23%
Jun 2022	—	—	22%	28%	20%
Sep 2022	—	−945%	40%	14%	20%
Dec 2022	—	−644%	53%	10%	−11%
Mar 2023	—	−428%	33%	3.9%	7.1%
Jun 2023	—	−297%	43%	21%	17%
Sep 2023	—	−280%	42%	23%	−3.7%
Dec 2023	38%	−27%	44%	20%	17%
Mar 2024	81%	−51%	49%	11%	15%
Jun 2024	−931%	−370%	51%	−43%	43%
Sep 2024	−887%	−167%	56%	15%	35%
Dec 2024	74%	0.2%	59%	23%	29%
Mar 2025	−68%	−96%	53%	21%	34%
Jun 2025	−758%	−34%	62%	26%	38%
Sep 2025	−985%	5.1%	62%	32%	43%
Dec 2025	−677%	1.0%	56%	26%	39%
Mar 2026	−6.5%	10%	49%	26%	41%
Jun 2026	74%	65%	60%	42%	40%
Sep 2026	—	—	—	—	—

Margin change, by reported quarter

Protagonist Therapeutics, Inc. +832.4 pp
Ascendis Pharma A/S +98.5 pp
Halozyme Therapeutics, Inc. −2.4 pp
Incyte Corporation +16.3 pp
Exelixis, Inc. +1.9 pp

−5000+500+1,000+1,500+832.4 pp

Margin change, by reported quarter
Quarter	Protagonist Therapeutics, Inc.	Ascendis Pharma A/S	Halozyme Therapeutics, Inc.	Incyte Corporation	Exelixis, Inc.
Dec 2021	—	—	—	—	—
Mar 2022	—	—	—	—	—
Jun 2022	−3,461.2 pp	+9,206.2 pp	−45.8 pp	+8.4 pp	−11.9 pp
Sep 2022	—	+7,764.0 pp	−25.4 pp	−15.1 pp	+4.4 pp
Dec 2022	—	+1,655.3 pp	−2.3 pp	−2.7 pp	−37.2 pp
Mar 2023	—	+1,447.3 pp	−31.3 pp	−13.0 pp	−16.3 pp
Jun 2023	—	+2,006.3 pp	+20.3 pp	−7.2 pp	−3.4 pp
Sep 2023	—	+665.3 pp	+2.1 pp	+9.2 pp	−23.8 pp
Dec 2023	—	+617.1 pp	−9.2 pp	+9.7 pp	+28.4 pp
Mar 2024	—	+376.6 pp	+15.6 pp	+6.6 pp	+7.5 pp
Jun 2024	—	−73.0 pp	+8.0 pp	−63.8 pp	+26.8 pp
Sep 2024	—	+112.5 pp	+14.3 pp	−8.4 pp	+38.5 pp
Dec 2024	+35.9 pp	+26.8 pp	+15.0 pp	+2.7 pp	+11.7 pp
Mar 2025	−149.1 pp	−44.6 pp	+4.6 pp	+10.2 pp	+19.0 pp
Jun 2025	+173.0 pp	+336.7 pp	+11.5 pp	+68.2 pp	−5.8 pp
Sep 2025	−98.5 pp	+172.4 pp	+5.2 pp	+16.6 pp	+8.1 pp
Dec 2025	−751.4 pp	+0.8 pp	−2.6 pp	+2.9 pp	+10.6 pp
Mar 2026	+61.7 pp	+105.9 pp	−4.4 pp	+4.9 pp	+7.5 pp
Jun 2026	+832.4 pp	+98.5 pp	−2.4 pp	+16.3 pp	+1.9 pp
Sep 2026	—	—	—	—	—

23 of 30 companies report OPM, 27 of 30 margin change. The margin change chart is drawn inside its usual range; a quarter far outside it (often a first quarter after listing or a near-zero base) is marked with an arrow at the edge, with its exact value in the hover card and the table.

OPM · highest

Margin change · fastest expanders

1Spyre Therapeutics, Inc.SYRE+999.3 pp
2Protagonist Therapeutics, Inc.PTGX+832.4 pp
3Kymera Therapeutics, Inc.KYMR+620.5 pp
4Insmed IncorporatedINSM+212.6 pp
5ImmunityBio, Inc.IBRX+149.4 pp

All-company data · latest reported quarter

Operating margin, every company
Company	OPM	Margin change	Reported
Protagonist Therapeutics, Inc. PTGX	74%	+832.4 pp	Jun 2026
Ascendis Pharma A/S ASND	65%	+98.5 pp	Jun 2026
Halozyme Therapeutics, Inc. HALO	60%	−2.4 pp	Jun 2026
Incyte Corporation INCY	42%	+16.3 pp	Jun 2026
Exelixis, Inc. EXEL	40%	+1.9 pp	Jun 2026
Vertex Pharmaceuticals Incorporated VRTX	38%	−0.8 pp	Jun 2026
argenx SE ARGX	36%	+5.9 pp	Sep 2026
Genmab A/S GMAB	35%	−3.7 pp	Jun 2026
Regeneron Pharmaceuticals, Inc. REGN	33%	+3.5 pp	Jun 2026
Bio-Techne Corporation TECH	28%	+1.8 pp	Jun 2026
Jazz Pharmaceuticals plc JAZZ	27%	+6.0 pp	Jun 2026
BioMarin Pharmaceutical Inc. BMRN	21%	−12.3 pp	Jun 2026
Royalty Pharma plc RPRX	20%	−19.1 pp	Jun 2026
BeOne Medicines AG ONC	19%	+12.4 pp	Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY	18%	+20.0 pp	Jun 2026
Caris Life Sciences, Inc. CAI	10%	+20.1 pp	Jun 2026
Madrigal Pharmaceuticals, Inc. MDGL	−16%	+6.7 pp	Jun 2026
Insmed Incorporated INSM	−24%	+212.6 pp	Jun 2026
BridgeBio Pharma, Inc. BBIO	−44%	+76.8 pp	Jun 2026
Kymera Therapeutics, Inc. KYMR	−116%	+620.5 pp	Jun 2026
ImmunityBio, Inc. IBRX	−120%	+149.4 pp	Jun 2026
Revolution Medicines, Inc. RVMD	−403%	−20,417.3 pp	Jun 2026
Moderna, Inc. MRNA	−558%	+80.8 pp	Jun 2026
Spyre Therapeutics, Inc. SYRE	−561%	+999.3 pp	Jun 2026
BioNTech SE BNTX	−807%	−641.6 pp	Jun 2026
Roivant Sciences Ltd. ROIV	−945%	−12,375.3 pp	Jun 2026
Summit Therapeutics Inc. SMMT	—	−6,211.4 pp	Jun 2026

What to watch

Watch whether the next two comparable periods confirm the current margin change rather than reversing it.

Which Biotechnology companies earn the most profit?

Vertex Pharmaceuticals Incorporated has the highest Net profit among the 30 Biotechnology companies compared here, at $4,405 million. Regeneron Pharmaceuticals, Inc. is next at $4,329 million. Incyte Corporation has the highest Profit growth at 85.3%, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Vertex Pharmaceuticals Incorporated earns the most, $4,405 million of profit over the last 12 months, 1.8% above Regeneron Pharmaceuticals, Inc. Incyte Corporation shows 85.3% growth from a profit base of $1,612 million. A fast rate from a small base matters less than a large profit that keeps coming.

Vertex Pharmaceuticals Incorporated · $4,405 millionLeader

1.8% versus #2 · Regeneron Pharmaceuticals, Inc.Gap

5/8 recent comparable periodsPersistence

30/30 companies · 559 observationsCoverage

What this means: Vertex Pharmaceuticals Incorporated sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit, by reported quarter

Vertex Pharmaceuticals Incorporated $1.1B
Regeneron Pharmaceuticals, Inc. $1.3B
argenx SE $506M
Incyte Corporation $586M
Jazz Pharmaceuticals plc $193M

−$4.0B−$2.0B$0M$2.0B$4.0B$1.1B

Net profit, by reported quarter
Quarter	Vertex Pharmaceuticals Incorporated	Regeneron Pharmaceuticals, Inc.	argenx SE	Incyte Corporation	Jazz Pharmaceuticals plc
Dec 2021	$770M	$2.2B	−$238M	$564M	−$35M
Mar 2022	$762M	$974M	−$227M	$38M	$2M
Jun 2022	$811M	$852M	−$209M	$161M	$35M
Sep 2022	$931M	$1.3B	−$235M	$113M	−$20M
Dec 2022	$819M	$1.2B	−$39M	$28M	−$241M
Mar 2023	$700M	$818M	−$29M	$22M	$69M
Jun 2023	$916M	$968M	−$94M	$204M	$104M
Sep 2023	$1.0B	$1.0B	−$73M	$171M	$147M
Dec 2023	$969M	$1.2B	−$99M	$201M	$94M
Mar 2024	$1.1B	$722M	−$62M	$170M	−$15M
Jun 2024	−$3.6B	$1.4B	$29M	−$445M	$169M
Sep 2024	$1.0B	$1.3B	$91M	$106M	$215M
Dec 2024	$913M	$918M	$774M	$201M	$191M
Mar 2025	$646M	$809M	$169M	$158M	−$93M
Jun 2025	$1.0B	$1.4B	$246M	$405M	−$719M
Sep 2025	$1.1B	$1.5B	$344M	$424M	$251M
Dec 2025	$1.2B	$845M	$533M	$299M	$203M
Mar 2026	$1.0B	$727M	$366M	$303M	$293M
Jun 2026	$1.1B	$1.3B	$472M	$586M	$193M
Sep 2026	—	—	$506M	—	—

Profit growth, by reported quarter

Vertex Pharmaceuticals Incorporated 6.5%
Regeneron Pharmaceuticals, Inc. −6.8%
argenx SE 47%
Incyte Corporation 45%
Jazz Pharmaceuticals plc 6.3%

−500%−250%0%250%500%750%6.5%

Profit growth, by reported quarter
Quarter	Vertex Pharmaceuticals Incorporated	Regeneron Pharmaceuticals, Inc.	argenx SE	Incyte Corporation	Jazz Pharmaceuticals plc
Dec 2021	—	—	—	—	—
Mar 2022	—	—	—	—	—
Jun 2022	1,110%	−73%	−301%	8.1%	—
Sep 2022	9.3%	−19%	—	−38%	—
Dec 2022	6.4%	−46%	—	−95%	—
Mar 2023	−8.1%	−16%	—	−42%	3,350%
Jun 2023	13%	14%	—	27%	197%
Sep 2023	11%	−23%	—	51%	—
Dec 2023	18%	−3.1%	—	618%	—
Mar 2024	57%	−12%	—	673%	−122%
Jun 2024	−492%	48%	—	−318%	63%
Sep 2024	1.0%	33%	—	−38%	46%
Dec 2024	−5.8%	−21%	—	0.0%	103%
Mar 2025	−41%	12%	—	−7.1%	—
Jun 2025	—	−2.8%	748%	—	−525%
Sep 2025	3.6%	8.9%	278%	300%	17%
Dec 2025	30%	−8.0%	−31%	49%	6.3%
Mar 2026	60%	−10%	117%	92%	—
Jun 2026	6.5%	−6.8%	92%	45%	—
Sep 2026	—	—	47%	—	—

30 of 30 companies report net profit, 9 of 30 profit growth. The profit growth chart is drawn inside its usual range; a quarter far outside it (often a first quarter after listing or a near-zero base) is marked with an arrow at the edge, with its exact value in the hover card and the table.

Net profit · largest

1Vertex Pharmaceuticals IncorporatedVRTX$4.4B
2Regeneron Pharmaceuticals, Inc.REGN$4.3B
3argenx SEARGX$1.9B
4Incyte CorporationINCY$1.6B
5Jazz Pharmaceuticals plcJAZZ$940M

Profit growth · fastest growers

1Incyte CorporationINCY85%
2Exelixis, Inc.EXEL43%
3argenx SEARGX22%
4Vertex Pharmaceuticals IncorporatedVRTX21%
5Regeneron Pharmaceuticals, Inc.REGN−2.9%

All-company data · latest reported quarter

Net profit, every company
Company	Net profit	Profit growth	Reported
Regeneron Pharmaceuticals, Inc. REGN	$1.3B	−6.8%	Jun 2026
Vertex Pharmaceuticals Incorporated VRTX	$1.1B	6.5%	Jun 2026
Incyte Corporation INCY	$586M	45%	Jun 2026
argenx SE ARGX	$506M	47%	Sep 2026
Genmab A/S GMAB	$303M	−9.8%	Jun 2026
BeOne Medicines AG ONC	$237M	152%	Jun 2026
Halozyme Therapeutics, Inc. HALO	$230M	39%	Jun 2026
Exelixis, Inc. EXEL	$212M	15%	Jun 2026
Ascendis Pharma A/S ASND	$207M	—	Jun 2026
Jazz Pharmaceuticals plc JAZZ	$193M	6.3%	Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY	$164M	−176%	Jun 2026
Protagonist Therapeutics, Inc. PTGX	$163M	−133%	Jun 2026
Bio-Techne Corporation TECH	$55M	122%	Jun 2026
BioMarin Pharmaceutical Inc. BMRN	$45M	−81%	Jun 2026
Royalty Pharma plc RPRX	$18M	−44%	Jun 2026
Caris Life Sciences, Inc. CAI	−$1M	—	Jun 2026
Insmed Incorporated INSM	−$13M	—	Jun 2026
Spyre Therapeutics, Inc. SYRE	−$31M	−124%	Jun 2026
Madrigal Pharmaceuticals, Inc. MDGL	−$58M	—	Jun 2026
Kymera Therapeutics, Inc. KYMR	−$61M	—	Jun 2026
Apogee Therapeutics, Inc. APGE	−$86M	—	Jun 2026
Nuvalent, Inc. NUVL	−$109M	—	Mar 2026
BridgeBio Pharma, Inc. BBIO	−$152M	—	Jun 2026
Summit Therapeutics Inc. SMMT	−$216M	—	Jun 2026
ImmunityBio, Inc. IBRX	−$230M	—	Jun 2026
Vaxcyte, Inc. PCVX	−$284M	—	Jun 2026
Roivant Sciences Ltd. ROIV	−$291M	−366%	Jun 2026
Revolution Medicines, Inc. RVMD	−$644M	—	Jun 2026
Moderna, Inc. MRNA	−$782M	−1,638%	Jun 2026
BioNTech SE BNTX	−$821M	−217%	Jun 2026

What to watch

Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.

Which Biotechnology companies earn the best return on capital?

Exelixis, Inc. has the highest ROCE among the 30 Biotechnology companies compared here, at 46.5%. Halozyme Therapeutics, Inc. is next at 42.3%. Ascendis Pharma A/S has the highest ROCE change at +175.1 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Exelixis, Inc. leads ROCE at 46.5%, 4.2 percentage points above Halozyme Therapeutics, Inc. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

Exelixis, Inc. · 46.5%Leader

9.9% versus #2 · Halozyme Therapeutics, Inc.Gap

8/8 recent comparable periodsPersistence

30/30 companies · 547 observationsCoverage

What this means: Exelixis, Inc. sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

ROCE, by reported quarter

Exelixis, Inc. 47%
Halozyme Therapeutics, Inc. 42%
Incyte Corporation 28%
Alnylam Pharmaceuticals, Inc. 25%
Vertex Pharmaceuticals Incorporated 21%

−50%−25%0%25%50%75%47%

ROCE, by reported quarter
Quarter	Exelixis, Inc.	Halozyme Therapeutics, Inc.	Incyte Corporation	Alnylam Pharmaceuticals, Inc.	Vertex Pharmaceuticals Incorporated
Dec 2021	13%	28%	15%	−24%	35%
Mar 2022	16%	29%	15%	−24%	34%
Jun 2022	13%	15%	17%	−27%	33%
Sep 2022	14%	14%	14%	−29%	31%
Dec 2022	7.3%	17%	13%	−28%	28%
Mar 2023	5.2%	17%	11%	−29%	28%
Jun 2023	5.0%	19%	8.8%	−32%	26%
Sep 2023	1.6%	19%	10%	−12%	24%
Dec 2023	6.7%	21%	12%	−9.9%	23%
Mar 2024	8.4%	22%	12%	−6.1%	22%
Jun 2024	17%	22%	2.0%	3.5%	25%
Sep 2024	24%	24%	0.6%	−6.3%	23%
Dec 2024	27%	29%	2.2%	−5.8%	23%
Mar 2025	33%	29%	5.2%	−3.7%	22%
Jun 2025	32%	36%	21%	−5.5%	22%
Sep 2025	34%	53%	25%	8.0%	22%
Dec 2025	37%	35%	25%	14%	22%
Mar 2026	43%	37%	25%	20%	21%
Jun 2026	47%	42%	28%	25%	21%
Sep 2026	—	—	—	—	—

ROCE change, by reported quarter

Exelixis, Inc. +14.4 pp
Halozyme Therapeutics, Inc. +6.7 pp
Incyte Corporation +6.8 pp
Alnylam Pharmaceuticals, Inc. +30.2 pp
Vertex Pharmaceuticals Incorporated −1.4 pp

−200+20+40+14.4 pp

ROCE change, by reported quarter
Quarter	Exelixis, Inc.	Halozyme Therapeutics, Inc.	Incyte Corporation	Alnylam Pharmaceuticals, Inc.	Vertex Pharmaceuticals Incorporated
Dec 2021	—	—	—	—	—
Mar 2022	—	—	—	—	—
Jun 2022	—	—	—	—	—
Sep 2022	—	—	—	—	—
Dec 2022	−5.3 pp	−11.0 pp	−2.0 pp	−4.3 pp	−6.1 pp
Mar 2023	−10.6 pp	−12.0 pp	−4.3 pp	−5.3 pp	−5.5 pp
Jun 2023	−8.0 pp	+4.1 pp	−7.9 pp	−4.9 pp	−6.3 pp
Sep 2023	−12.2 pp	+4.7 pp	−3.3 pp	+16.3 pp	−6.4 pp
Dec 2023	−0.6 pp	+4.1 pp	−0.9 pp	+18.4 pp	−5.9 pp
Mar 2024	+3.2 pp	+5.7 pp	+1.9 pp	+22.9 pp	−6.1 pp
Jun 2024	+11.6 pp	+2.6 pp	−6.8 pp	+35.1 pp	−1.0 pp
Sep 2024	+22.1 pp	+4.8 pp	−9.7 pp	+6.0 pp	−1.1 pp
Dec 2024	+20.4 pp	+7.7 pp	−9.6 pp	+4.1 pp	+0.7 pp
Mar 2025	+25.0 pp	+6.9 pp	−7.2 pp	+2.4 pp	+0.1 pp
Jun 2025	+15.5 pp	+13.6 pp	+19.3 pp	−9.0 pp	−3.0 pp
Sep 2025	+9.8 pp	+29.6 pp	+24.0 pp	+14.3 pp	−0.9 pp
Dec 2025	+9.5 pp	+6.1 pp	+22.5 pp	+20.1 pp	−1.7 pp
Mar 2026	+9.7 pp	+8.0 pp	+19.7 pp	+23.6 pp	−0.8 pp
Jun 2026	+14.4 pp	+6.7 pp	+6.8 pp	+30.2 pp	−1.4 pp
Sep 2026	—	—	—	—	—

30 of 30 companies report ROCE, 30 of 30 ROCE change.

ROCE · highest

1Exelixis, Inc.EXEL47%
2Halozyme Therapeutics, Inc.HALO42%
3Incyte CorporationINCY28%
4Alnylam Pharmaceuticals, Inc.ALNY25%
5Vertex Pharmaceuticals IncorporatedVRTX21%

ROCE change · fastest improvers

1Ascendis Pharma A/SASND+175.1 pp
2Summit Therapeutics Inc.SMMT+153.0 pp
3ImmunityBio, Inc.IBRX+35.6 pp
4Caris Life Sciences, Inc.CAI+34.9 pp
5Alnylam Pharmaceuticals, Inc.ALNY+30.2 pp

All-company data · latest reported quarter

Return on capital, every company
Company	ROCE	ROCE change	Reported
Exelixis, Inc. EXEL	47%	+14.4 pp	Jun 2026
Halozyme Therapeutics, Inc. HALO	42%	+6.7 pp	Jun 2026
Incyte Corporation INCY	28%	+6.8 pp	Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY	25%	+30.2 pp	Jun 2026
Vertex Pharmaceuticals Incorporated VRTX	21%	−1.4 pp	Jun 2026
argenx SE ARGX	19%	+11.4 pp	Sep 2026
Caris Life Sciences, Inc. CAI	15%	+34.9 pp	Jun 2026
Ascendis Pharma A/S ASND	14%	+175.1 pp	Jun 2026
BeOne Medicines AG ONC	13%	+15.6 pp	Jun 2026
Jazz Pharmaceuticals plc JAZZ	13%	+5.3 pp	Jun 2026
Genmab A/S GMAB	12%	−9.1 pp	Jun 2026
Regeneron Pharmaceuticals, Inc. REGN	12%	0.0 pp	Jun 2026
Bio-Techne Corporation TECH	11%	+1.9 pp	Jun 2026
Royalty Pharma plc RPRX	8.1%	−2.7 pp	Jun 2026
Protagonist Therapeutics, Inc. PTGX	6.9%	+3.4 pp	Jun 2026
BioMarin Pharmaceutical Inc. BMRN	4.9%	−6.6 pp	Jun 2026
BioNTech SE BNTX	−10%	−6.2 pp	Jun 2026
Kymera Therapeutics, Inc. KYMR	−22%	+7.9 pp	Jun 2026
Spyre Therapeutics, Inc. SYRE	−25%	+24.2 pp	Jun 2026
Apogee Therapeutics, Inc. APGE	−25%	+18.3 pp	Jun 2026
Roivant Sciences Ltd. ROIV	−27%	−1.6 pp	Jun 2026
Moderna, Inc. MRNA	−29%	+2.5 pp	Jun 2026
Nuvalent, Inc. NUVL	−35%	−3.8 pp	Mar 2026
Madrigal Pharmaceuticals, Inc. MDGL	−37%	+0.7 pp	Jun 2026
Vaxcyte, Inc. PCVX	−41%	−18.1 pp	Jun 2026
Revolution Medicines, Inc. RVMD	−41%	−1.0 pp	Jun 2026
ImmunityBio, Inc. IBRX	−46%	+35.6 pp	Jun 2026
Insmed Incorporated INSM	−49%	−6.0 pp	Jun 2026
Summit Therapeutics Inc. SMMT	−135%	+153.0 pp	Jun 2026
BridgeBio Pharma, Inc. BBIO	−146%	−74.9 pp	Jun 2026

What to watch

Watch whether the next two comparable periods confirm the current roce change rather than reversing it.

How are Biotechnology stocks valued against growth and quality?

Genmab A/S has the lowest PEG among the 30 Biotechnology companies compared here, at 0.21×. Halozyme Therapeutics, Inc. is next at 0.25×. Roivant Sciences Ltd. has the lowest P/E at −66.1×, so level and change sit with different companies. 11 of 30 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Genmab A/S has the lowest comparable PEG at 0.21×, 16% below Halozyme Therapeutics, Inc. That would need today's multiple, the company's own history and steady growth to agree.

Genmab A/S · 0.21×Leader

16% versus #2 · Halozyme Therapeutics, Inc.Gap

0/8 recent comparable periodsPersistence

11/30 companies · 37 observationsCoverage

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG, by reported quarter

Genmab A/S 0.2
Halozyme Therapeutics, Inc. 0.3
Exelixis, Inc. 0.3
Jazz Pharmaceuticals plc 0.3
Royalty Pharma plc 0.3

012340.2

PEG, by reported quarter
Quarter	Genmab A/S	Halozyme Therapeutics, Inc.	Exelixis, Inc.	Jazz Pharmaceuticals plc	Royalty Pharma plc
Dec 2021	—	—	—	—	—
Mar 2022	—	—	—	—	—
Jun 2022	—	—	—	—	—
Sep 2022	—	—	—	—	—
Dec 2022	—	—	—	—	—
Mar 2023	—	—	—	—	—
Jun 2023	3.9	—	—	—	—
Sep 2023	—	0.7	—	—	—
Dec 2023	—	0.4	2.2	—	—
Mar 2024	2.2	—	0.9	—	—
Jun 2024	0.8	0.4	—	—	—
Sep 2024	1.3	—	—	—	—
Dec 2024	—	—	—	0.3	—
Mar 2025	0.2	0.3	—	—	0.4
Jun 2025	—	—	—	—	0.3
Sep 2025	—	0.3	0.3	—	—
Dec 2025	—	—	0.3	—	—
Mar 2026	—	—	0.4	—	—
Jun 2026	—	—	0.3	—	—
Sep 2026	—	—	—	—	—

P/E, by reported quarter

Genmab A/S 21.4×
Halozyme Therapeutics, Inc. 22.5×
Exelixis, Inc. 15.9×
Jazz Pharmaceuticals plc 16.1×
Royalty Pharma plc 30.5×

−200×0×200×400×21.4×

P/E, by reported quarter
Quarter	Genmab A/S	Halozyme Therapeutics, Inc.	Exelixis, Inc.	Jazz Pharmaceuticals plc	Royalty Pharma plc
Dec 2021	56.0×	14.1×	25.0×	—	27.6×
Mar 2022	65.7×	12.6×	24.3×	−21.4×	28.0×
Jun 2022	36.2×	16.6×	24.5×	−187.8×	39.3×
Sep 2022	26.9×	25.8×	16.4×	—	34.7×
Dec 2022	36.9×	38.1×	—	—	—
Mar 2023	34.7×	28.5×	40.9×	−59.3×	48.1×
Jun 2023	38.6×	20.9×	37.9×	−91.9×	54.0×
Sep 2023	38.8×	19.9×	75.6×	102.2×	66.1×
Dec 2023	33.2×	17.3×	35.9×	18.7×	11.0×
Mar 2024	24.9×	16.2×	35.1×	—	17.0×
Jun 2024	20.0×	19.8×	18.7×	17.0×	17.7×
Sep 2024	22.3×	18.5×	15.9×	14.9×	11.1×
Dec 2024	11.3×	13.7×	18.2×	13.3×	13.2×
Mar 2025	10.6×	16.2×	16.1×	—	12.3×
Jun 2025	9.8×	11.5×	20.0×	—	14.8×
Sep 2025	12.4×	14.4×	16.4×	−21.7×	19.9×
Dec 2025	20.4×	—	15.1×	−29.0×	21.3×
Mar 2026	19.8×	22.0×	13.4×	395.0×	24.8×
Jun 2026	21.4×	22.5×	15.9×	16.1×	30.5×
Sep 2026	—	—	—	—	—

11 of 30 companies report PEG, 20 of 30 P/E.

PEG · lowest PEG

P/E · lowest P/E

1Roivant Sciences Ltd.ROIV−66.1×
2BioNTech SEBNTX−39.7×
3Caris Life Sciences, Inc.CAI−14.2×
4Moderna, Inc.MRNA−11.6×
5Spyre Therapeutics, Inc.SYRE−8.2×

All-company data · latest reported quarter

Valuation, every company
Company	PEG	P/E	Reported
Bio-Techne Corporation TECH	8.3	60.5×	Jun 2026
BioMarin Pharmaceutical Inc. BMRN	6.1	151.6×	Jun 2026
Protagonist Therapeutics, Inc. PTGX	2.2	95.1×	Jun 2026
Regeneron Pharmaceuticals, Inc. REGN	2.1	14.7×	Jun 2026
argenx SE ARGX	1.4	32.0×	Sep 2026
Vertex Pharmaceuticals Incorporated VRTX	1.3	28.6×	Jun 2026
Royalty Pharma plc RPRX	0.3	30.5×	Jun 2026
Exelixis, Inc. EXEL	0.3	15.9×	Jun 2026
Jazz Pharmaceuticals plc JAZZ	0.3	16.1×	Jun 2026
Halozyme Therapeutics, Inc. HALO	0.3	22.5×	Jun 2026
Genmab A/S GMAB	0.2	21.4×	Jun 2026
Moderna, Inc. MRNA	—	−11.6×	Jun 2026
BeOne Medicines AG ONC	—	48.3×	Jun 2026
Roivant Sciences Ltd. ROIV	—	−66.1×	Jun 2026
Incyte Corporation INCY	—	14.1×	Jun 2026
BioNTech SE BNTX	—	−39.7×	Jun 2026
Alnylam Pharmaceuticals, Inc. ALNY	—	49.7×	Jun 2026
Ascendis Pharma A/S ASND	—	20.8×	Jun 2026
Caris Life Sciences, Inc. CAI	—	−14.2×	Jun 2026
Spyre Therapeutics, Inc. SYRE	—	−8.2×	Jun 2026

What to watch

Watch whether the next two comparable periods confirm the current p/e rather than reversing it.

What can make this comparison misleading?

This Biotechnology comparison names 5 specific ways its own evidence can mislead, all listed below. 1 of the 30 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. A high growth rate can still come from a very small starting figure.

Keep these limits visible

A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.

How was this comparison built?

This comparison is built from the reported filings of 30 Biotechnology companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 4 November 2026.

FundamentalsThrough Sep 2026 · up to 20 quarters per company

Market dataThrough 4 November 2026 · weekly price and relative-strength history

Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.

Score confidenceMissing and old evidence lowers confidence and pulls the 0 to 100 score toward the middle.

What else do people ask about Biotechnology stocks?

These 22 answers restate the Biotechnology comparison above in question form. Every one is computed from the same 30 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 4 November 2026. Nothing here is estimated, and none of it is a recommendation.

Is the Biotechnology sector outperforming S&P 500?

Biotechnology has done better than the S&P 500 by 55.3% over 52 weeks and by 16.7% over 13 weeks.

21 of 30 companies we track are beating the S&P 500 on relative strength (how a share price has done against the index over recent months) (3 have no relative-strength reading yet), and 10 of the 27 with a long enough price history are ahead of the industry itself.

Which Biotechnology company is largest by revenue?

Regeneron Pharmaceuticals, Inc. leads with revenue of $15,534 million, based on 24 of 30 comparable companies through Jun 2026.

Which Biotechnology company is growing fastest?

Ascendis Pharma A/S has the fastest current revenue growth at 100%, across 24 of 30 comparable companies.

Which Biotechnology company has the strongest 4-Factor Sector Score?

Exelixis, Inc. ranks first at 76 out of 100, with 81.1% of the evidence available. The score ranks published data; it is not a recommendation.

Which Biotechnology company has the lowest comparable PEG?

Genmab A/S has the lowest comparable PEG at 0.21, among 11 of 30 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Biotechnology comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.

Which Biotechnology company is the biggest?

Regeneron Pharmaceuticals, Inc. is the largest, with revenue of $15,534 million over the last 12 months, ahead of Vertex Pharmaceuticals Incorporated at $12,587 million. That covers 24 of 30 companies with comparable reporting through Jun 2026.

Which Biotechnology company has the best profit margins?

Protagonist Therapeutics, Inc. has the highest operating margin at 74.4%, from 23 of 30 comparable companies. Spyre Therapeutics, Inc. shows the biggest improvement (+999.3 percentage points; the chart above shows the starting level).

A high margin matters most when it is steady or rising, not when it is at a peak.

Which Biotechnology company makes the most profit?

Vertex Pharmaceuticals Incorporated earns the most, at $4,405 million of net profit over the last 12 months, from 30 of 30 comparable companies. Incyte Corporation has the fastest profit growth at 85.3%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Biotechnology company earns the highest return on capital?

Exelixis, Inc. leads on return on capital employed at 46.5%, across 30 of 30 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.

Which Biotechnology stock has the lowest PEG ratio?

On PEG (where a lower number means a lower price for what the company earns), Genmab A/S has the lowest at 0.21×. Only 11 of 30 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a ranking of the whole industry.

A low multiple is a reason to look closer at the business, not a conclusion on its own.

Is the Biotechnology sector beating the market?

Biotechnology has done better than the S&P 500 by 55.3% over the last 52 weeks and by 16.7% over 13 weeks, measured on an equal-weight index of its current members.

Inside the sector, 21 of the 30 companies we track are beating the market on their own (3 have no relative-strength reading yet). Sector strength does not transfer evenly to every stock in it.

Which Biotechnology stock has the strongest price momentum?

Moderna, Inc. has the strongest relative strength against the S&P 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.

Which Biotechnology company has the highest 4-Factor score?

Exelixis, Inc. scores 76 out of 100, with 81.1% of the evidence available, from 22.9 points on growth and earnings, 21 on capital efficiency, 14.4 on valuation and 17.7 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.

How many Biotechnology companies does this comparison cover, and over what period?

This comparison covers 30 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.

What is the total market cap of the Biotechnology sector?

The 30 Biotechnology companies on this page carry $875,890 million of combined market value. Vertex Pharmaceuticals Incorporated is the largest at $139,268 million, about 16% of the sector's total on its own. Market value moves with price, so this reading is dated 4 November 2026.

What is the Biotechnology sector's P/E ratio?

The median price-to-earnings ratio across the 30 Biotechnology companies on this page is 28.6×, measured on the 15 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past.

Figures are as of 4 November 2026.

How is the Biotechnology sector performing?

21 of the 30 Biotechnology companies we track are doing better than the S&P 500 on relative strength (how a share price has done against the index over recent months) (3 have no relative-strength reading yet).

The sector itself is 55.3% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members.

How many Biotechnology stocks are listed in the US?

This comparison covers 30 listed Biotechnology companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Sep 2026. Membership is the full industry list, nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.

Is this advice?

No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.

More lists

Every Sector Alpha list, grouped

Every US industry against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 4 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.

Which are the biggest Biotechnology stocks in the US?

Which are the Biotechnology stocks, ranked?

Which Biotechnology companies are listed in the US?

How many Biotechnology companies are listed in the US?

How has Biotechnology moved against S&P 500?

Is Biotechnology outperforming S&P 500?

What is the bottom line on Biotechnology?

How does each Biotechnology stock score?

Ranked last: too little evidence (4 companies)

How have Biotechnology share prices moved?

Price and relative strength

Biggest one-year moves

Strongest against S&P 500

Strongest against the sector itself

Which Biotechnology companies have the most revenue, and which grow fastest?

Revenue · company comparison

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

What to watch

Which Biotechnology companies keep the most from each $100 of sales?

Operating margin · company comparison

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

What to watch

Which Biotechnology companies earn the most profit?

Net profit · company comparison

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

What to watch

Which Biotechnology companies earn the best return on capital?

Return on capital · company comparison

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

What to watch

How are Biotechnology stocks valued against growth and quality?

Valuation · company comparison

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

What to watch

What can make this comparison misleading?

Keep these limits visible

How was this comparison built?

What else do people ask about Biotechnology stocks?

Is the Biotechnology sector outperforming S&P 500?

Which Biotechnology company is largest by revenue?

Which Biotechnology company is growing fastest?

Which Biotechnology company has the strongest 4-Factor Sector Score?

Which Biotechnology company has the lowest comparable PEG?

How much history does this Biotechnology comparison include?

How is the 4-Factor Sector Score calculated?

Which Biotechnology company is the biggest?

Which Biotechnology company has the best profit margins?

Which Biotechnology company makes the most profit?

Which Biotechnology company earns the highest return on capital?

Which Biotechnology stock has the lowest PEG ratio?

Is the Biotechnology sector beating the market?

Which Biotechnology stock has the strongest price momentum?

Which Biotechnology company has the highest 4-Factor score?

How many Biotechnology companies does this comparison cover, and over what period?

What is the total market cap of the Biotechnology sector?

What is the Biotechnology sector's P/E ratio?

How is the Biotechnology sector performing?

How many Biotechnology stocks are listed in the US?

Why are some values on this page blank?

Is this advice?

More lists

Stock screens

Market lists

Themes

Sectors

US stocks

Crypto